4-Year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer

European Urology

Volumn 38, Issue 6, 2000, Pages 706-713

  Schulman, Claude C ^a   Debruyne, Frans M J ^b   Forster, Gerhard ^c   Selvaggi, Francesco P ^d   Zlotta, Alexandre R ^a   Witjes, Wim P J ^b  

^a ERASME HOSPITAL   (Belgium)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Urologische Klinik Planegg   (Germany)

^d UNIVERSITY OF BARI   (Italy)

Author keywords

Flutamide; Goserelin; Hormone antagonists; Prostatectomy; Prostatic neoplasms

Indexed keywords

FLUTAMIDE; GOSERELIN; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER STAGING; CLINICAL RESEARCH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; PROSTATECTOMY; RANDOMIZED CONTROLLED TRIAL;

EID: 0033662583     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1159/000020366     Document Type: Article

References (27)

1. The clinical usefulness of prostate specific antigen: Update 1994
2. Correlation of pathological findings with progression following radical prostatectomy
3. Studies on prostatic cancer: The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate
4. Neoadjuvant hormonal therapy in carcinoma of the prostate
5. Neoadjuvant hormonal treatment prior to radical prostatectomy: Facts and open questions
6. Current status of neoadjuvant therapy in localized prostate cancer
7. Preliminary results of a prospective randomized study comparing radical prostatectomy versus radical prostatectomy associated with neoadjuvant hormonal combination therapy in T2-3 N0 M0 prostatic carcinoma
8. Hormonal treatment before radical prostatectomy: A 3-year followup
9. Downstaging of localized prostate cancer by neoadjuvant therapy with flutamide and lupron: The first controlled and randomized trial
10. Randomized, prospective, controlled study comparing radical prostatectomy alone and neoadjuvant androgen withdrawal in the treatment of localized prostate cancer
11. Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer
12. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: A randomized comparative trial of the Radiation Therapy Oncology Group
13. How to explore the patient with a rising PSA after radical prostatec-tomy: Defining local versus systemic failure
14. Neoadjuvant hormonal deprivation in patients with locally advanced prostate cancer
15. Neoadjuvant hormonal therapy and radical prostatectomy for clinical stage C carcinoma of the prostate
16. Histopathological effect of combination therapy on normal prostate and prostatic adenocar-cinoma
17. The utility of basal cell-specific anti-cytokeratin antibody (34 beta E12) in the diagnosis of prostate cancer. A review of 228 cases
18. Longer duration of neoadjuvant hormonal therapy prior to radical prostatectomy in clinically confined prostate cancer: Biochemical and pathological effects
19. Neoadjuvant androgen ablation prior to radical prostatectomy: Quantum leap or hope unrealized?
20. High Gleason score predicts poor pathologic outcome after neoadjuvant androgen deprivation for locally advanced prostate cancer
21. Radical prostatectomy alone vs. radical prostatecto-my preceded by androgen blockade in cT2b prostate cancer-24 months results
22. Neoadjuvant hormone therapy before radical prostatectomy: Update on phase II and III Memorial Sloan-Ketterin Cancer Center Trials
23. Neoadjuvant cyproterone acetate (CPA) therapy prior to radical prostatec-tomy reduces tumour burden and margin positivity without altering 6 and 12 month post-treatment PSA. Results of a randomised trial
24. Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with locally confined prostate cancer
25. Long-term neoadju-vant hormone therapy prior to radical prosta-tectomy: Analysis of outcome by preoperative risk factors
26. The role of neoadjuvant hormonal manipulation in localized prostate cancer